Elixir Medical has introduced the novel DynamX sirolimus-eluting coronary bioadaptor system to enhance coronary luminal diameter, restore haemodynamic modulation, and reduce plaque progression in patients with symptomatic ischaemic heart disease caused by discrete dae novo native coronary artery lesions.
The DynamX bioadaptor features a unique design and mechanism aimed at restoring the diseased vessel to a more normal condition through three distinct phases. Initially, in the locked phase post-implantation, it establishes maximum flow lumen to alleviate symptoms of coronary artery disease (CAD).
The second phase occurs after tissue encapsulation and absorption of the polymer coating, allowing the bioadaptor's helical strands to unlock and separate. This facilitates vessel growth and adaptation to maintain the established blood flow lumen.
In the third phase, the separated helical strands provide adaptive dynamic support to the vessel, restoring pulsatility, compliance, adaptive blood flow volume, and contributing to plaque stabilisation and regression.
The DynamX bioadaptor marks a major breakthrough as the pioneering coronary implant technology aimed at revitalizing coronary artery hemodynamic modulation. This is evidenced by restored vessel pulsatility, enhanced compliance, and increased adaptive blood flow volume, and stabilization and regression of plaque.
This innovative approach addresses limitations observed in traditional drug-eluting stents and bioresorbable scaffolds, with clinical data indicating notably low event rates maintained between one- and two-year follow-ups.
